I 
118TH CONGRESS 
2D SESSION 
H. R. 7283 
To direct the Comptroller General of the United States to evaluate and 
report on the inpatient and outpatient treatment capacity, availability, 
and needs of the United States. 
IN THE HOUSE OF REPRESENTATIVES 
FEBRUARY 7, 2024 
Mr. FOSTER introduced the following bill; which was referred to the Com-
mittee on Energy and Commerce, and in addition to the Committee on 
Natural Resources, for a period to be subsequently determined by the 
Speaker, in each case for consideration of such provisions as fall within 
the jurisdiction of the committee concerned 
A BILL 
To direct the Comptroller General of the United States to 
evaluate and report on the inpatient and outpatient 
treatment capacity, availability, and needs of the United 
States. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Examining Opioid 
Treatment Infrastructure Act of 2024’’. 
VerDate Sep 11 2014 
01:14 Feb 11, 2024
Jkt 049200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H7283.IH
H7283
ssavage on LAPJG3WLY3PROD with BILLS
SEC. 2. STUDY ON TREATMENT INFRASTRUCTURE. 
Not later than 24 months after the date of enactment 
of this Act, the Comptroller General of the United States 
shall initiate an evaluation of, and submit to Congress a 
report on, the inpatient and outpatient treatment capacity, 
availability, and needs of the United States, including, to 
the extent data are available— 
(1) the capacity of acute residential or inpatient 
detoxification programs; 
(2) the capacity of inpatient clinical stabiliza-
tion programs, transitional residential support serv-
ices, and residential rehabilitation programs; 
(3) the capacity of demographic specific resi-
dential or inpatient treatment programs, such as 
those designed for pregnant women or adolescents; 
(4) geographical differences of the availability 
of residential and outpatient treatment and recovery 
options for substance use disorders across the con-
tinuum of care; 
(5) the availability of residential and outpatient 
treatment programs that offer treatment options 
based on reliable scientific evidence of efficacy for 
the treatment of substance use disorders, including 
the use of Food and Drug Administration-approved 
medicines and evidence-based nonpharmacological 
therapies; 
VerDate Sep 11 2014 
01:14 Feb 11, 2024
Jkt 049200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H7283.IH
H7283
ssavage on LAPJG3WLY3PROD with BILLS
(6) the number of patients in residential and 
specialty outpatient treatment services for substance 
use disorders; 
(7) an assessment of the need for residential 
and outpatient treatment for substance use disorders 
across the continuum of care; 
(8) the availability of residential and outpatient 
treatment programs to American Indians and Alaska 
Natives through an Indian health program (as de-
fined by section 4 of the Indian Health Care Im-
provement Act (25 U.S.C. 1603)); and 
(9) the barriers (including technological bar-
riers) at the Federal, State, and local levels to real- 
time reporting of de-identified information on drug 
overdoses and ways to overcome such barriers. 
Æ 
VerDate Sep 11 2014 
22:48 Feb 12, 2024
Jkt 049200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6301
E:\BILLS\H7283.IH
H7283
ssavage on LAPJG3WLY3PROD with BILLS